<DOC>
	<DOC>NCT03066661</DOC>
	<brief_summary>Expanded access to entrectinib will be given to patients with cancers harboring NTRK1/2/3, ROS1, or ALK gene fusions who do not qualify for participation in, or who are otherwise unable to access, an ongoing clinical trial for entrectinib.</brief_summary>
	<brief_title>Expanded Access to Entrectinib for Cancers With NTRK1/2/3, ROS1, or ALK Gene Fusions</brief_title>
	<detailed_description />
	<criteria>Diagnosis of advanced cancer with an NTRK1, NTRK2, NTRK3, ROS1, or ALK gene fusion Unable to participate in an ongoing entrectinib (RXDX101) clinical trial Willing and able to provide written, signed informed consent Medically suitable for treatment with entrectinib (RXDX101) Currently enrolled in an ongoing clinical study with any other investigational agent</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>